Cervista® HPV: The Next Generation in HPV Testing
Cervista HPV HR is the first FDA-approved high-risk HPV test designed to detect all 14 oncogenic strains of HPV and reduce false-positive results associated with low-risk cross reactivity. In addition, Cervista HPV HR contains a unique internal control to validate that sufficient DNA is present for testing. With Cervista HPV HR, you can be more confident in your HPV test results.
Patented Invader chemistry powers the Cervista HPV tests. Using signal amplification and fluorescence detection, Cervista HPV identifies the presence of highly oncogenic types of the HPV virus. See how this advanced technology delivers a better HPV test.
The Cervista HPV HR clinical trial met or exceeded all objectives and proved comparable to those from the landmark ASC-US LSIL Triage Study (ALTS). The test’s negative predictive value (NPV) and detection rate for CIN3+ exceeded ALTS levels, underscoring its ability to identify patients most at risk for cervical cancer.
Get answers to common questions about Cervista HPV HR and HPV testing.
Cervista HPV HR and Cervista HPV 16/18 are approved for use with the ThinPrep® Pap Test. These tests work together to deliver the high sensitivity of HPV testing with the high specificity of Pap testing. Both the Cervista HPV HR and the ThinPrep Pap Test provide highly accurate results, a welcome advance for both physicians and women concerned about their risk of cervical cancer.
Cervista HPV 16/18 is the first HPV genotyping test approved by the FDA to identify and differentiate high-risk types 16 and 18. Types 16 and 18 are known to be both highly oncogenic and persistent, together associated with over 70% of all cervical cancers. See why typing these two strains allows you to tailer your patients care.